Kit or device and method for detecting hippocampal atrophy
US-2023212675-A1 · Jul 6, 2023 · US
US12529104B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12529104-B2 |
| Application number | US-201916969328-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 12, 2019 |
| Priority date | Feb 13, 2018 |
| Publication date | Jan 20, 2026 |
| Grant date | Jan 20, 2026 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
An embodiment according to the present invention provides a kit or device for detection of dementia, and a method for detecting dementia. An embodiment according to the present invention relates to: a kit or device for detection of dementia, including a nucleic acid(s) capable of specifically binding to an miRNA(s) or a complementary strand(s) thereof in a sample from a subject; and a method for detecting dementia, including measuring the miRNA(s) in vitro.
Opening claim text (preview).
The invention claimed is: 1 . A method for detecting dementia, comprising measuring expression levels of the polynucleotides of dementia markers: miR-6088 and miR-211-5p in a sample from a subject; and evaluating in vitro whether or not the subject has dementia using the measured expression levels of only miR-6088 and miR-211-5p. 2 . The method according to claim 1 , comprising plugging the gene expression levels of the polynucleotides in the sample from the subject into a discriminant formula capable of discriminating dementia or non-dementia distinctively, wherein the discriminant formula is created by using gene expression levels in samples from subjects known to have dementia and gene expression levels in samples from non-dementia subjects as training samples; and thereby evaluating whether or not the subject has dementia. 3 . The method according to claim 1 , wherein the expression levels of the target genes in the sample from the subject are measured by using a kit for detection of dementia, comprising nucleic acids capable of specifically binding polynucleotides of dementia markers: or to complementary strands of the polynucleotides. 4 . The method according to claim 1 , the subject is a human. 5 . The method according to claim 1 , the sample is blood, serum, or plasma.
Expression markers · CPC title
Hybridisation assays · CPC title
Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection · CPC title
miRNA, siRNA or ncRNA · CPC title
for diseases caused by alterations of genetic material · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.